Alcon AG vs Taskus Inc — how do they compare? Alcon AG trades at $75.11 (market cap $35.19B), while Taskus Inc trades at $7.1 (market cap $650.52M). The key difference: Alcon AG is far larger — about 54.1× Taskus Inc's market cap, and Alcon AG pays a 0.49% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| ALC | TASK | |
|---|---|---|
Market Cap | $35.19B | $650.52M |
Sector | Health | Technology |
52-Week High | $90.12 | $18.21 |
52-Week Low | $62.02 | $4.57 |
Enterprise Value | $39.03B | $1.02B |
Dividend Yield | 0.49% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
TaskUs (TASK) trades at $7.30, down 6.65% today, but maintains strong fundamentals with Q2 2026 revenue beating guidance by $10.9 million. The stock shows bullish technical signals with support at $7 and bullish moving averages. Valuation metrics appear attractive with P/E of 6.29 and P/S of 0.55, while profitability remains solid with 8.75% net margin and 25.43% ROE. Recent CFO appointment and AI services growth provide positive catalysts.
The outlook remains positive with analyst consensus favoring Buy ratings (54.55%) and improving cash flow trends. Key opportunities include undervaluation relative to earnings power and AI services expansion. Risks include client concentration and potential earnings volatility. The combination of reasonable valuation and growth momentum supports a constructive view for patient investors.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →